[{"orgOrder":0,"company":"AM-Pharma","sponsor":"Cowen Healthcare Investments","pharmaFlowCategory":"D","amount":"$176.0 million","upfrontCash":"Undisclosed","newsHeadline":"AM-Pharma Increases Funding To \u20ac163m For Phase-Iii Trial Of Recap In Sa-Aki","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Enrolls First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Enrollment and Financing of Covid-19 Cohort in Phase III Revival Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KBI Biopharma Enters Commercial Manufacturing Agreement with AM-Pharma to Prepare for the Commercial Launch Acute Kidney Disease Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Two Presentations at the 27th International Conference on Advances in Critical Care Nephrology","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$290.0 million","upfrontCash":"$23.6 million","newsHeadline":"AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"400 Patients Have Been Enrolled in AM-Pharma\u2019s Pivotal Phase 3 Study of Ilofotase Alfa for the Treatment of Sepsis-associated Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Publication of In Vivo Acute Kidney Injury Study Demonstrating Ilofotase Alfa\u2019s Dual Protective Mechanism","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-pharma Provides Business Update And Outcome Of Pre-planned Interim Futility Analysis Of Phase 3 Revival Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Updated Clinical Development Strategy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Positive Clinical Data From Phase 1b Study Evaluating Ilofotase Alfa in Hypophosphatasia Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Initiates Phase 2 Trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by AM-Pharma
recAP (Ilofotase Alfa) is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase. It is under phase 2 clinical development for the treatment of cardiac surgery-associated renal damage.
Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, which is investigated for enzyme replacement therapy in adult hypophosphatasia (HPP) patients.
Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, which is investigated for cardiac surgery-associated renal damage.
Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that in multiple clinical trials was shown to be stable and highly active.
Study shows ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury in rodents through the activation of adenosine receptors and the metabolism of extracellular adenosine triphosphate (ATP), a pro-inflammatory molecule.
Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that in multiple clinical trials was shown to be stable and highly active.
Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that was shown in multiple clinical trials to be stable and highly active.
Under the terms of the agreement, AM-Pharma is entitled to tiered double-digit royalties on sales and a drug supply fee. Kyowa Kirin will gain the exclusive right to develop and commercialize ilofotase alfa in Japan.
The REVIVAL trial is a Phase III pivotal study evaluating AM-Pharma’s proprietary recombinant alkaline phosphatase, ilofotase alfa, for the treatment of patients with SA-AKI.
Lead Product(s):
Recombinant Human Alkaline Phosphatase
KBI will conduct manufacturing and validation in its existing facilities. AM-Pharma and KBI Biopharma began collaborating on the recAP program in 2011 when KBI performed initial process development and cGMP manufacturing for early clinical use.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
